Risk of Latent Tuberculosis Infection Reactivation in Patients Treated with Tumor Necrosis Factor Antagonists: A Five-Year Retrospective Study

Basit Öğe Kaydı
dc.authorid0000-0002-7496-0026
dc.authorid0000-0002-4740-1579
dc.authorid0009-0006-3755-026X
dc.contributor.authorAliravci, Isil Deniz
dc.contributor.authorMutlu, Pinar
dc.contributor.authorOymak, Sibel
dc.contributor.authorGuney, Ufuk Ilter
dc.contributor.authorKeskin, Oguzhan
dc.date.accessioned2026-02-03T11:59:48Z
dc.date.available2026-02-03T11:59:48Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: This study aims to reveal the demographic and clinical data of patients receiving TNF-alpha blockers, to compare the characteristics of those who received latent tuberculosis infection (LTBI) treatment and those who did not, and to evaluate and determine potential risk factors for developing active TB disease. Methods: A systematic retrospective study was conducted in a tertiary university hospital examining all patients receiving at least one TNF-alpha blocker between January 2019 and October 2024. The incidence of tuberculosis (TB) was analyzed across various TNF-alpha blocker medications in patients, both with and without LTBI treatment. Results: A total of 519 patients had TNF-alpha blockers: 452 (87.09%) underwent TST, 193 (37.1%) underwent booster TST, and 33 (6.3%) underwent IGRA/TST; 362 (69.7%) were treated for LTBI, and 7 (1.3%) developed TB. Comparing all TNF-alpha blockers, adalimumab showed a higher risk of TB. Patients with and without LTBI treatment did not significantly differ in TB incidence after biologic therapy. Conclusions: The incidence of TB in people taking TNF-alpha blockers was higher compared to the incidence in the general population. LTBI screening, including both TST and IGRA, should be performed with TST and IGRA tests, and LTBI-positive individuals should be started on preventive treatment. However, it should not be forgotten that active TB disease may also develop in LTBI-negative individuals.
dc.description.sponsorshipCanakkale Provincial Health Directorate
dc.description.sponsorshipWe would like to thank the Canakkale Provincial Health Directorate for their great help and support in this study.
dc.identifier.doi10.3390/tropicalmed10070190
dc.identifier.issn2414-6366
dc.identifier.issue7
dc.identifier.pmid40711067
dc.identifier.scopus2-s2.0-105011666338
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3390/tropicalmed10070190
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34426
dc.identifier.volume10
dc.identifier.wosWOS:001539662800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofTropical Medicine and Infectious Disease
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20260130
dc.subjectTNF-alpha blockers
dc.subjectretrospective
dc.subjectlatent tuberculosis infection
dc.subjecttuberculosis
dc.titleRisk of Latent Tuberculosis Infection Reactivation in Patients Treated with Tumor Necrosis Factor Antagonists: A Five-Year Retrospective Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu